Market Research Industry Reports

Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H2 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H2 2018, provides an overview of the Neuromyelitis Optica (Devics Syndrome) (Central Nervous System) pipeline landscape.

Neuromyelitis optica (NMO), also known as Devics disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a persons immune system (the bodys natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devics Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuromyelitis Optica (Devics Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devics Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 1, 6, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Neuromyelitis Optica (Devics Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devics Syndrome) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Devics Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuromyelitis Optica (Devics Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuromyelitis Optica (Devics Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devics Syndrome) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Devics Syndrome) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devics Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 4
Neuromyelitis Optica (Devics Syndrome) - Overview 5
Neuromyelitis Optica (Devics Syndrome) - Therapeutics Development 6
Neuromyelitis Optica (Devics Syndrome) - Therapeutics Assessment 14
Neuromyelitis Optica (Devics Syndrome) - Companies Involved in Therapeutics Development 22
Neuromyelitis Optica (Devics Syndrome) - Drug Profiles 28
Neuromyelitis Optica (Devics Syndrome) - Dormant Projects 99
Neuromyelitis Optica (Devics Syndrome) - Discontinued Products 100
Neuromyelitis Optica (Devics Syndrome) - Product Development Milestones 101
Appendix 109

List Of Tables


Number of Products under Development for Neuromyelitis Optica (Devics Syndrome), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Abide Therapeutics Inc, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Acer Therapeutics Inc, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Biogen Inc, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Bionure Farma SL, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Boston Pharmaceuticals Inc, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Endece LLC, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by HanAll Biopharma Co Ltd, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by LFB SA, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Tolerion Inc, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Vicore Pharma AB, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Dormant Projects, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Discontinued Products, H2 2018

List Of Figures


Number of Products under Development for Neuromyelitis Optica (Devics Syndrome), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2018

Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H2 2018, provides an overview

USD 2000View Report

Neuromyelitis Optica (Devic’s Syndrome) Global Clinical Trials Review, H1, 2018

Neuromyelitis Optica (Devics Syndrome) Global Clinical Trials Review, H1, 2018GlobalDatas clinical trial report, Neuromyelitis Optica (Devics Syndrome) Global Clinical Trials Review, H1, 2018 provides an overview of Neuromyelitis Optica (Devics

USD 2500View Report

Neuromyelitis Optica (Devic’s Syndrome) Global Clinical Trials Review, H1, 2018

Neuromyelitis Optica (Devics Syndrome) Global Clinical Trials Review, H1, 2018GlobalDatas clinical trial report, Neuromyelitis Optica (Devics Syndrome) Global Clinical Trials Review, H1, 2018 provides an overview of Neuromyelitis Optica (Devics

USD 2500View Report

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H1 2018

Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H1 2018, provides an overview

USD 2000View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Sep 2018
No. of Pages :113
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube